Novavax, Inc. (NVAX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Novavax, Inc. is a biotechnology company focused on vaccine development, utilizing its recombinant protein-based nanoparticle technology and Matrix-M adjuvant. The company's strategic priorities include its partnership with Sanofi Pasteur, enhancing existing collaborations (e.g., Takeda, Serum Institute of India), and advancing its early-stage pipeline. The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Revenue | $239,240 | $415,484 | $905,895 | $509,339 |
| Net Income | $106,508 | $162,381 | $625,154 | $14,831 |
| Diluted EPS | $0.62 | $0.99 | $3.55 | $0.10 |
| Operating Cash Flow | — | — | ($312,964) | $230,714 |
| Cash & Equivalents | $253,744 | — | — | — |
| Marketable Securities | $358,560 | — | — | — |
| Total Debt (Convertible Notes) | $170,568 | — | — | — |
Note: Q2 2024 and 6-month 2024 cash balance data is not explicitly provided in the text for the specific line item comparison, but the 6-month 2024 ending cash balance was $695,558.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue for Q2 2025 decreased 42% compared to Q2 2024, primarily due to a significant drop in licensing revenue from the Sanofi Collaboration and License Agreement (Sanofi CLA). However, revenue for the six months ended June 30, 2025, increased 78% year-over-year. This increase was driven by the recognition of $575.7 million in product sales resulting from the termination of the Canada Advanced Purchase Agreement (APA) and $27.3 million from the New Zealand APA settlement.
- Profitability: Net income for the six months ended June 30, 2025, surged to $625.2 million compared to $14.8 million in the prior year period. This was driven by the APA termination revenue and a 41% reduction in total expenses due to restructuring and cost containment measures.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased 57% in Q2 2025 compared to Q2 2024, and 51% for the six-month period, reflecting a leaner operating model and the sale of the Novavax CZ manufacturing facility.
- Cash Flow: Operating cash flow turned negative for the six months ended June 30, 2025, with a use of $313.0 million, compared to a provision of $230.7 million in the prior year. This shift is attributed to reduced cash receipts from APAs and changes in working capital.
Guidance, Outlook, and Risks
- Sanofi Partnership: The company expects to receive a $175 million milestone payment in Q3 2025 related to the U.S. FDA approval of the Nuvaxovid BLA. Additional milestones totaling $50 million are expected in Q4 2025 upon the transfer of marketing authorization to Sanofi in the U.S. and EU.
- Regulatory Risks: The company faces uncertainty regarding the Australia APA. If regulatory approval for the updated vaccine is not received by December 31, 2025, up to $92.5 million of deferred revenue may become refundable. The company withdrew its application at the request of the Therapeutic Goods Administration (TGA) and is discussing new regulatory paths.
- Post-Marketing Commitment (PMC): The U.S. FDA requires a Phase 4 efficacy and safety trial for the Nuvaxovid vaccine. Novavax will conduct this trial, with Sanofi reimbursing 70% of the costs.
- Going Concern: Management has concluded that the company has sufficient capital to fund operations for at least one year from the filing date, citing cash, marketable securities, and expected milestone payments.
- Legal Proceedings: A derivative settlement was finalized in March 2025, resulting in a net gain of $4.8 million recorded in Q1 2025. Other litigation has been dismissed or stayed.
Investor Verification Checklist
- APA Termination Revenue: Verify the sustainability of revenue streams following the one-time recognition of $603 million from Canada and New Zealand APA terminations.
- Australia APA Status: Monitor the regulatory timeline with the TGA to assess the risk of refunding up to $92.5 million in deferred revenue.
- Sanofi Milestone Timing: Confirm the receipt of the $175 million Q3 2025 milestone and the $50 million Q4 2025 milestones.
- Operating Cash Burn: Analyze the shift to negative operating cash flow and the company's ability to fund R&D and the PMC trial without additional equity financing.
- Regulatory Environment: Assess the impact of the new U.S. administration's policies on ACIP recommendations and FDA approval pathways for COVID-19 vaccines.